Bionxt Solutions Inc.

BNXTF

$0.33Apr 30, 2021Apr 30, 2026
Health CarePharmaceuticals$42M
MVM
-$2.1M
BLE
-2.282
PositiveNegativeNo data· Dot size = magnitude · Scroll to zoom · Drag to pan
Chart Start
$1.99
2021
Since 2021
-83.6%
vs SPY +71.3%
All-time High
$2.14 · May 2021
-84.8% from peak
MVM Rank
#210 of 311
Pharmaceuticals
Reaction Win Rate
46%
12 of 26 events

Bionxt Solutions Inc. has returned -83.6% from $1.99 since 2021, trailing SPY's +71.3% over the same period. The stock hit an all-time high of $2.14 in May 2021 and is currently 84.8% below that level. Of 26 tracked news events, 46% produced a positive market-adjusted return.

How to use this page
1Company Research Snapshot

Expand to read Wikipedia-sourced background on the company. Click any linked term to explore it inline — no page reload.

2Company Q&A

Common questions answered from real data: performance vs SPY, market cap, profitability, CEO, dividends, and more.

3News & Events

Every dot on the chart is a news event. The return shown is market-adjusted (vs SPY). Green = stock outperformed. Red = underperformed. Dot size = magnitude of reaction.

Company Q&AShow ▼
Hover to inspect

Want the full written briefing?

The chart shows what moved — the briefing shows why. Sourced, dated, no hot takes.

Subscribe on Substack →

News Events

DateReturnCategorySourceHeadline
2022-02-01+25.7%expansionSeeking AlphaXPhyto executes COVID-ID lab sales contracts in Germany
2023-04-29+18.3%earningsZacks Investment ResearchWhat date does BioNxt Solutions Inc.'s (BNXTF) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research
2023-03-07+16.2%M&ASeeking AlphaBioNxt acquires rights for solid oral drug technology
2026-04-07-11.4%newsMT NewswiresBioNxt Solutions Registers Its ODF Platform With the European Patent Office
2026-04-07-11.4%newsACCESS NewswireBioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
2026-04-07-11.4%expansionStock Titan18-country patent gives BioNxt one legal path for Europe launch - Stock Titan
2022-10-05+11.2%newsSeeking AlphaXPhyto inks LOI for US manufacturing and strategic business opportunities
2024-02-19-8.6%expansionSeeking AlphaBioNxt Solutions finalizes debt settlement agreement
2025-12-17-7.9%executiveScott CoopOver 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies - Scott Coop
2023-03-01+7.2%expansionSeeking AlphaBioNxt signs agreement to study Rotigotine patch for Parkinsons disease
2026-04-14+7.0%newsStock TitanNeedle-free MS drug film clears final step before human trial - Stock Titan
2026-04-28-6.6%analystACCESS NewswireBioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
2026-04-28-6.6%analyst富途牛牛BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum - 富途牛牛
2026-03-24+5.6%newsACCESS NewswireBioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
2026-03-24+5.6%newsStock TitanBioNxt takes MS drug film toward market with patents spanning 1 billion people - Stock Titan
2022-11-10-2.8%executiveSeeking AlphaXPhyto Therapeutics to be renamed BioNxt Solutions
2026-03-30-2.6%newsACCESS NewswireBioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
2025-07-24-2.4%newsStock TitanGSTK Stock Price, News & Analysis - Stock Titan
2026-02-17+2.1%newsACCESS NewswireBioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
2026-03-17+2.0%expansionACCESS NewswireBioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
2022-12-12-2.0%newsSeeking AlphaBioNxt Solutions signs term sheet for drug coating platform
2026-02-05+2.0%newsACCESS NewswireBioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
2025-04-25-0.8%newsStock TitanDUTV Stock Price, News & Analysis - Stock Titan
2023-08-07-0.4%newsSeeking AlphaBioNxt Solutions announces ~$4M private placement
2023-04-17-0.4%newsSeeking AlphaBioNxt buys state-of-the-art coating and cutting equipment to build out European commercial manufacturing capacity
2026-02-27+0.4%legalACCESS NewswireBioNxt Announces Closing of Shares for Debt Settlement
tickerdossier.comtickerdossier.substack.com